Ramtin Agah - 21 Jan 2026 Form 4 Insider Report for RenovoRx, Inc. (RNXT)

Reporting relationship
Chief Medical Officer, Director
Issuer ticker
RNXT
Reported as of
21 Jan 2026
Net transaction value
+$9,975
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
22 Jan 2026, 07:00:18 UTC
Prior SEC filing
05 Jan 2026
Next SEC filing
07 Apr 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Ramtin Agah

Key filing fact

Ramtin Agah filed Form 4 for RenovoRx, Inc. (RNXT) on 22 Jan 2026.

Key facts

  • This page summarizes Ramtin Agah's Form 4 filing for RenovoRx, Inc. (RNXT).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 22 Jan 2026, 07:00.

Change

  • Previous filing in this sequence was filed on 05 Jan 2026.
  • Current net transaction value: +$9,975.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001862617 Primary reporting owner

Agah Ramtin

Relationship
Chief Medical Officer, Director
Address
C/O RENOVORX, INC., 2570 W EL CAMINO REAL, SUITE 320, MOUNTAIN VIEW
Signature
/s/ Ramtin Agah
Signature date
22 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RNXT transaction

Common Stock

Purchase

Transaction value
$9,975
Shares
+10,000
Change %
+1.3%
Price
$0.9975
Shares after
798,460
Date
21 Jan 2026
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Reflects open market purchases of the Issuer's securities.

Footnote F2

Reflects a weighted average price. The securities were purchased in multiple transactions at per share prices ranging from $0.995 to $1.00.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .